Bender Robert & Associates’s Clovis Oncology CLVS Stock Holding History
Bought
Maintained
Sold
Other funds holding CLVS
Bender Robert & Associates's CLVS Position: Q4 2022 in Review
Bender Robert & Associates sold out of Clovis Oncology (CLVS) in Q4 2022, closing a stake of 50,000 shares — an estimated $60K sold.
Bender Robert & Associates first reported a position in CLVS in Q1 2021 and held it in 3 quarters. The position peaked at $351K in Q1 2021. 14 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.
- Bender Robert & Associates reported no remaining Clovis Oncology position as of Q4 2022 after selling out during the quarter.
- Bender Robert & Associates sold 50,000 Clovis Oncology shares in Q4 2022, an estimated $60K.
- Bender Robert & Associates first reported a position in Clovis Oncology in Q1 2021 and held it in 3 quarters.
- Bender Robert & Associates's Clovis Oncology position peaked at $351K in Q1 2021.
- 14 funds tracked by Wall St. Rank held Clovis Oncology as of Q4 2022.
Based on Bender Robert & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.